Focused On-demand Library for Tetratricopeptide repeat protein 19, mitochondrial

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q6DKK2

UPID:
TTC19_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q6DKK2; A8MZ52; B3KP62; B4DN65; Q2M248; Q7L3U8; Q9H6G3; Q9NXB2

BACKGROUND:
The mitochondrial protein Tetratricopeptide repeat protein 19 (TPR19) is pivotal for the preservation of mitochondrial respiratory complex III. It ensures the removal of detrimental N-terminal fragments of UQCRFS1, a key component for the complex's function, thereby safeguarding cellular energy processes.

THERAPEUTIC SIGNIFICANCE:
Given TPR19's critical role in mitochondrial complex III deficiency, nuclear type 2, exploring its function further could unveil new therapeutic avenues. Understanding the role of TPR19 could open doors to potential therapeutic strategies for combating mitochondrial diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.